Literature DB >> 20304208

Exclusions and deaths on the liver transplant waiting list.

V Cadahía1, M L González-Diéguez, P Alonso, C García-Bernardo, A Miyar de León, L Barneo, L Vázquez, I M González-Pinto, M Rodríguez.   

Abstract

OBJECTIVE: To analyze the characteristiscs, evolution and survival of patients included on the waiting list (WL) for liver transplantation (OLT). PATIENTS AND METHODS: Between February 2002 and April 2009, 254 patients were included on WL to receive a first graft. Two hundred twenty-two patients (87.4%) were transplanted (group T); 7 (2.8%) died on the WL and 25 (9.8%) were excluded, namely, 13 (52%) due to improvement (group IE) and 12, for other reasons (group OE). Data collected prospectively were analyzed retrospectively.
RESULTS: Indications for transplant were cirrhosis (58%), hepatocellular carcinoma (HCC; 29%) and other etiologies (13%.) Average time on the WL was 60.3 +/- 62.9 days. Significant differences were not observed among the groups with respect to age, gender, or indication for OLT. The probability for exclusion due to progression and/or death was not significantly greater among patients included for HCC than for other reasons (P = .6). Survivals at 1, 3, and 5 years after WL inclusion were 81.2%, 73.3%, and 68.6%, respectively, in the whole series; and 85,4%, 76,9%, and 71.7% in group T. All group OE patients died before the first year, while group IE showed a survival of 100%, 91.7% and 91.7% at 1, 3, and 5 years, respectively. Survival was not different between groups T and IE (P = .03), but was lower in group OE than in groups T or IE (P < .001).
CONCLUSION: The list mortality rate in our series was low, probably in relation to the short waiting time. The rate of exclusion from WL was 10%. Patient with hepatocellular carcinoma were not at an increased risk of WL exclusion. Patients excluded due to improvement displayed excellent survivals during the 5 years following exclusion. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20304208     DOI: 10.1016/j.transproceed.2010.02.009

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis.

Authors:  P A Cortesi; L G Mantovani; A Ciaccio; M Rota; C Mazzarelli; G Cesana; M Strazzabosco; L S Belli
Journal:  Am J Transplant       Date:  2015-07       Impact factor: 8.086

2.  Survival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study.

Authors:  Sudul Mananjala Senanayake; Madunil Anuk Niriella; Sanjaya Kumara Weerasinghe; Anuradhani Kasturiratne; Jerome Praneeth de Alwis; Arjuna Priyadarsin de Silva; Anuradha Supun Dassanayake; Hithanadura Janaka de Silva
Journal:  BMC Res Notes       Date:  2012-12-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.